CRAC intermediate 1 is primarily utilized in the research and development of CRAC channel inhibitors, which play a significant role in modulating calcium release-activated calcium channels. These channels are critical in immune cell signaling, particularly in T-cells, making CRAC intermediate 1 a valuable compound for studying autoimmune diseases, inflammatory conditions, and immune response regulation. It serves as a key intermediate in synthesizing potential therapeutic agents aimed at targeting conditions like rheumatoid arthritis, psoriasis, and other immune-related disorders. Additionally, its application extends to pharmacological studies focused on understanding calcium signaling pathways and their impact on cellular functions.